ArticleJournal of gastroenterology and hepatology2026
Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab as First-Line Systemic Therapy for Hepatocellular Carcinoma: A Real-World Study.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methodological Considerations Regarding a TriNetX Comparison of First-Line Therapies for HCC.Journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
aimsAtezolizumab plus bevacizumab (Atezo/Bev) and durvalumab plus tremelimumab (Durva/Treme) are established first-line therapies for advanced hepatocellular carcinoma (HCC). However, direct comparisons between these regimens remain limited. This study aimed to evaluate their comparative effectiveness and safety.
methodsWe conducted a retrospective cohort study within the TriNetX Global Collaborative Network, including adults with HCC who initiated Atezo/Bev or Durva/Treme as first-line systemic therapy between October 1, 2022, and October 31, 2025. Outcomes were defined using standardized diagnostic, procedural, and medication codes. Propensity score matching (1:1) was applied to minimize baseline differences between groups.
resultsAmong 3362 eligible patients, 765 matched pairs were included in the final analysis. Over a median follow-up of 14.8 months for Atezo/Bev and 17.5 months for Durva/Treme, overall survival was comparable between the regimens (median 14.6 vs. 17.3 months; aHR 0.96; 95% CI 0.83-1.12). Safety outcomes were broadly similar, including gastrointestinal bleeding (aHR 0.88; 95% CI 0.68-1.13) and non-gastrointestinal bleeding (aHR 1.06; 95% CI 0.60-1.89). Treatment-requiring immune-related adverse events (irAEs) occurred significantly less frequently with Atezo/Bev (aHR 0.61; 95% CI 0.48-0.77), with curve separation evident early after treatment initiation. Incident hypertension was numerically more frequent with Atezo/Bev but was not statistically significant (aHR 1.24; 95% CI 0.87-1.76).
conclusionsAtezo/Bev and Durva/Treme demonstrated similar overall survival in patients with HCC, with largely comparable safety profiles. The lower rate of treatment-requiring irAEs observed with Atezo/Bev may assist clinicians in tailoring regimen selection for individuals with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.